This is the current revision of this page, as edited by Bendegúz Ács(talk | contribs) at 18:46, 27 April 2024(Added study on inactivating mutations linked to lower risk of coronary heart disease). The present address (URL) is a permanent link to this version.
Revision as of 18:46, 27 April 2024 by Bendegúz Ács(talk | contribs)(Added study on inactivating mutations linked to lower risk of coronary heart disease)
As cancer appeared more frequently in patients treated with simvastatin-ezetimibe combination therapy in one clinical trial,[11] it had been hypothesized that NPC1L1 by ezetimibe might be associated with an increased cancer risk.[12] However, a meta-analysis of ezetimibe clinical data showed no increase in the risk of cancer from treatment with ezetimibe.[13]
^Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P (December 2015). "Safety and efficacy of ezetimibe: A meta-analysis". International Journal of Cardiology. 201: 247–52. doi:10.1016/j.ijcard.2015.08.103. PMID26301648.
Overview of all the structural information available in the PDB for UniProt: Q9UHC9 (Human NPC1-like intracellular cholesterol transporter 1) at the PDBe-KB.